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duardo Marba´n, MD, PHD,
onstantinos Malliaras, MD
os Angeles, California
tem cell transplantation is a promising new treatment for
schemic cardiomyopathy, offering the unique opportunity
or true cardiac repair and regeneration. Several different
ypes of stem and progenitor cells are being explored for this
urpose (1). Among the various cell types, mesenchymal
tem cells (MSCs) (alternatively named multipotent stromal
ells) are potentially attractive, as they are easily isolated and
xpanded, and they exhibit low immunogenicity, rendering
llogeneic applications plausible (2). Despite their potential
enefits, results in animal models and in humans have been
ariable, and little is known regarding their mechanism of
ction. Are all MSCs created equal? Can they really regen-
rate heart tissue directly? If so, is direct cardiomyogenesis
equired for a therapeutic effect?
See page 721
Mesenchymal stem cells, first described by Friedenstein
n 1961 (3), are self-renewing precursors of nonhematopoi-
tic stromal tissues characterized by: 1) adherence to plastic
n culture; 2) surface expression of CD105, CD90, and
D73; 3) lack of expression of hematopoietic markers; and
) the capacity to differentiate into fibroblasts, osteoblasts,
dipocytes, and chondroblasts under specific in vitro condi-
ions (4). Originally, MSCs were isolated from the bone
arrow, but similar populations have been reported in
everal other tissues including the heart (5). In vivo, MSCs
ypically reside in perivascular niches (6) where they create/
unction as a stromal network, supporting other cell types
e.g., hematopoietic cells in bone marrow) (7) and contrib-
ting to the creation and maintenance of connective tissues.
lthough traditional isolation of MSCs by plastic adherence
esults in notoriously heterogeneous preparations with re-
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isclose.pect to cell size, morphology, proliferative capacity, and
otential for differentiation (8), it is commonly accepted
hat these cells compose a multipotent adult stem cell
opulation, but their capacity to differentiate into excitable
issues is not well-established (2).
The ability of MSCs to undergo true cardiomyogenic
ransdifferentiation, in particular, remains highly controver-
ial (9,10). In vitro, MSCs can express cardiac-specific
roteins but do not display the typical electrical properties of
rue cardiomyocytes (10). In vivo, there is immunohistologic
vidence for low cardiac engraftment and transdifferentia-
ion after MSC transplantation (11), although such findings
re not universal (12), even within the same laboratory (13).
n order to boost aptitude for cardiomyogenic differentia-
ion, different strategies of MSC ex vivo manipulation have
een employed with various degrees of success, including
xposure of cells to the deoxyribonucleic acid demethylating
gent 5-azacytidine, pre-treatment with growth factors,
ypoxic pre-conditioning, and genetic engineering (2).
owever, there is still a lack of convincing evidence that
SCs can differentiate into functional cardiomyocytes.
In this issue of the Journal, landmark work by Behfar et
l. (14) investigates the feasibility of deriving cardiomyo-
ytes from human mesenchymal stem cells (hMSCs)
hrough mimicry of natural/embryonic cardiogenic signal-
ng. Bone marrow-derived hMSCs were isolated from
atients undergoing coronary artery bypass surgery. In their
aive state, hMSCs exhibited poor capacity for cardiomyo-
enic differentiation in vitro as well as limited potential for
yocardial repair in vivo. However, ex vivo priming of cells
ith a cardiogenic cocktail of growth factors (consisting of
ransforming growth factor-beta1, bone morphogenetic
rotein-4, activin-A, retinoic acid, insulin-like growth
actor-1, fibroblast growth factor-2, alpha-thrombin, and
nterleukin-6) up-regulated cytosolic expression and pro-
oted nuclear translocation of cardiac transcription factors,
uccessfully converting weakling hMSCs into ones capable
f strong cardiopoiesis. Importantly, this “boot camp” strat-
gy resulted in a dramatic improvement of functional and
tructural end points following intramyocardial injection
nto nude mice with ischemic cardiomyopathy. The inves-
igators provide the first convincing evidence that MSCs, at
east in vitro, can in fact become functional cardiomyocytes,
xhibiting sarcomerogenesis, mitochondrial maturation, and
lectromechanical coupling. Using a cocktail-based ap-
roach (previously employed by the same group to stimulate
ardiopoiesis of embryonic stem cells) (15) while avoiding
o-culture of MSCs with other cell types, the capacity of
one marrow-derived hMSCs to undergo cardiomyogenic
ransdifferentiation was convincingly established and distin-
uished from fusion phenomena.
Behfar et al. (14) further noted that naive MSCs dem-
nstrated vast interpatient heterogeneity in terms of their
ptitude for in vitro cardiomyogenic transdifferentiation and
otential for myocardial repair. Indeed, only 2 of 11
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iac transcription factors and the ability to boost ejection
raction in injured mouse hearts, but none of the clinical
haracteristics was predictive of the reparative cytotype. In
ontrast to some previous reports (11,12), but confirming
thers (16), treatment with naive hMSCs did not improve
ardiac function relative to saline-treated controls.
Because MSCs can be isolated from a variety of different
issues, including the heart (5,17), tissue of origin might be
f particular importance. It seems plausible that cells may
lready be primed toward differentiation along lineages
pecific to tissues in which they reside. Consistent with this
dea, the molecular profile, differentiation potential, and
unction can vary widely among MSC preparations depend-
ng on their origin (18,19). If tissue source proves to be
mportant, heart-derived MSCs merit particular investiga-
ion, as they may be more predisposed to cardiomyogenesis
han are bone marrow MSCs. They may also possess a
pecialized ability to support cardiac progenitor cells
CPCs) in the heart, just as bone marrow MSCs physio-
ogically support hematopoietic cells in the marrow.
A final notable aspect of the present study (14) is that a
SC-derived cardiopoietic cell phenotype (regardless of
hether it was observed spontaneously in rare individuals or
s a result of guided cardiopoiesis) was associated with a
ramatic increase in reparative efficacy, when compared
ith noncardiopoietic MSCs. This increase was attributed
o more robust direct (cardiomyogenesis, angiogenesis) and
ndirect (cardiomyocyte cell cycle re-entry, endogenous stem
Figure 1
Schematic Depiction of the Balance of
Direct Versus Indirect Mechanisms
Underlying the Salutary Effects of MSCs
Schematic depiction of the balance of direct (cardiomyogenesis, angiogenesis,
and favorable changes in tissue architecture) versus indirect (cell cycle re-
entry, recruitment of cardiac progenitor cells and secreted factors) mecha-
nisms underlying the salutary effects of mesenchymal stem cells (MSCs). Indi-
rect mechanisms predominate in naive MSCs, but the benefit is small: a child
tips the seesaw. Boot camp-conditioned MSCs exhibit balanced, robust mecha-
nisms, akin to the interplay of 2 physically-fit adults.ell recruitment) contributions to infarct repair by condi-
ioned cells compared to naive MSCs (Fig. 1). To date, the
ajority of in vivo studies have demonstrated at least
odest functional improvement following MSC transplan-
ation, despite undetectable to low levels of long-term
ngraftment and differentiation (12,20). This implies that
SCs exert their beneficial effects mainly through indirect
aracrine actions rather than by contributing directly to
issue regeneration (2,21). Importantly, the fact that signif-
cant long-term engraftment is not required for functional
enefit (20), together with the purportedly low immunoge-
icity (22) of MSCs, support the notion that allogeneic
ransplantation without immunosuppression may be feasi-
le. On the other hand, the positive correlation between
SC engraftment and functional recovery in post-ischemic
ardiomyopathy suggests that some of the benefit may be
ue to long-term engraftment and trilineage differentiation
f MSCs (11), even if the absolute survival of transplanted
ells is low.
A particularly important function of cardiac MSCs may
e to enhance the survival and/or potency of cotransplanted
PCs in cardiomyoplasty. We have been investigating
ardiosphere-derived cells (CDCs) grown from percutane-
us endomyocardial biopsies for human therapeutic appli-
ations. Cardiosphere-derived cells are a natural mixture of
eart-derived cell subpopulations, including true CPCs
c-kit/CD90–) as well as cardiac MSCs (c-kit–/CD90)
23,24). One logical approach to cardiomyoplasty is the
elective purification, expansion, and injection of CPCs
25,26). We find, however, that CDCs outperform purified
PCs. In experiments with intramyocardial injection of
uman CDCs in a mouse myocardial infarction model, the
pontaneously emerging unselected mixture of CPCs and
ardiac MSCs resulted in a higher ejection fraction at 3
eeks than either purified c-kit or CD90 cells from the
ame source (27). These findings hint that cardiac MSCs
elp CPCs to engraft and/or function, presumably via
ynergistic paracrine actions as well as direct myocardial
egeneration (28).
eprint requests and correspondence: Dr. Eduardo Marba´n, Heart
nstitute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los
ngeles, California 90048. E-mail: MarbanE@cshs.org.
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